Rvl Pharms Drug Patent Portfolio
Rvl Pharms owns 1 orange book drug protected by 12 US patents Given below is the list of Rvl Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10799481 | Compositions and methods for treating ocular disorders | 16 Dec, 2039 | Active |
| US10814001 | Oxymetazoline compositions | 16 Dec, 2039 | Active |
| US10898573 | Oxymetazoline compositions | 16 Dec, 2039 | Active |
| US10940138 | Compositions and methods for treating ocular disorders | 16 Dec, 2039 | Active |
| US11103482 | Oxymetazoline compositions | 16 Dec, 2039 | Active |
| US11311515 | Oxymetazoline compositions | 16 Dec, 2039 | Active |
| US11324722 | Compositions and methods for treating ocular disorders | 16 Dec, 2039 | Active |
| US11541036 | Oxymetazoline compositions | 16 Dec, 2039 | Active |
| US11701343 | Compositions and methods for treating ocular disorders | 16 Dec, 2039 | Active |
| US10912765 | Compositions and methods for non-surgical treatment of ptosis | 26 Aug, 2031 | Active |
| US8357714 | Compositions and methods for non-surgical treatment of ptosis | 26 Aug, 2031 | Active |
| US9867808 | Compositions and methods for non-surgical treatment of Ptosis | 26 Aug, 2031 | Active |
Latest Legal Activities on Rvl Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Rvl Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 17 Jul, 2024 | US8357714 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Apr, 2024 | US10799481 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Apr, 2024 | US10814001 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 18 Jul, 2023 | US11701343 |
|
Recordation of Patent Grant Mailed
Critical
| 18 Jul, 2023 | US11701343 |
|
Electronic Review
Critical
| 18 Jul, 2023 | US11701343 |
| Mail Patent eGrant Notification | 18 Jul, 2023 | US11701343 |
| Recordation of Patent eGrant | 18 Jul, 2023 | US11701343 |
|
Email Notification
Critical
| 18 Jul, 2023 | US11701343 |
| Patent eGrant Notification | 18 Jul, 2023 | US11701343 |
|
Electronic Review
Critical
| 07 Jul, 2023 | US11701343 |
|
Email Notification
Critical
| 07 Jul, 2023 | US11701343 |
|
Issue Notification Mailed
Critical
| 06 Jul, 2023 | US11701343 |
|
Electronic Review
Critical
| 29 Jun, 2023 | US11701343 |
|
Email Notification
Critical
| 29 Jun, 2023 | US11701343 |
Rvl Pharms's Family Patents
Rvl Pharms drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 36.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Rvl Pharms Drug List
Given below is the complete list of Rvl Pharms's drugs and the patents protecting them.
1. Upneeq
Upneeq is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10799481 | Compositions and methods for treating ocular disorders |
16 Dec, 2039
(14 years from now)
| Active |
| US10814001 | Oxymetazoline compositions |
16 Dec, 2039
(14 years from now)
| Active |
| US10898573 | Oxymetazoline compositions |
16 Dec, 2039
(14 years from now)
| Active |
| US10940138 | Compositions and methods for treating ocular disorders |
16 Dec, 2039
(14 years from now)
| Active |
| US11103482 | Oxymetazoline compositions |
16 Dec, 2039
(14 years from now)
| Active |
| US11311515 | Oxymetazoline compositions |
16 Dec, 2039
(14 years from now)
| Active |
| US11324722 | Compositions and methods for treating ocular disorders |
16 Dec, 2039
(14 years from now)
| Active |
| US11541036 | Oxymetazoline compositions |
16 Dec, 2039
(14 years from now)
| Active |
| US11701343 | Compositions and methods for treating ocular disorders |
16 Dec, 2039
(14 years from now)
| Active |
| US10912765 | Compositions and methods for non-surgical treatment of ptosis |
26 Aug, 2031
(6 years from now)
| Active |
| US8357714 | Compositions and methods for non-surgical treatment of ptosis |
26 Aug, 2031
(6 years from now)
| Active |
| US9867808 | Compositions and methods for non-surgical treatment of Ptosis |
26 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Upneeq's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List